BIOGEN IDEC (NASDAQ:BIIB)
46.38
+0.53 (1.16%)
| BIOGEN IDEC (NASDAQ:BIIB) Delayed : |
| Previous Close |
$45.85 |
|
52 Week High |
$55.34 |
|
| Open |
$45.60 |
|
52 Week Low |
$5.93 |
| Day High |
$46.52 |
|
P/E |
15.56 |
| Day Low |
$45.56 |
|
EPS |
$2.98 |
| Volume |
2,829,055 |
|
|
|
| More BIIB Info:
Chart
SEC Filings
Profile
Historical
Options
|
Biogen Idec Summary
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid ...more
Executives
James C. Mullen - CEO
Links
http://www.biogenidec.com
View All ReportsStreetInsider.com Reports on BIIB
-
Nov 2, 2009 09:43 AM
Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
-
Oct 23, 2009 12:52 PM
Unusual 11 Mid-Day Movers 10/23: AMZN, SCSS, ALGN, EPAY Higher; ELN, SNV, CBRX, STSA Lower
-
Oct 23, 2009 10:53 AM
Morning Movers 10/23: AMZN, CPWR, EPAY, ALGN, HWAY, SCSS, ACO Higher; ELN, SNV, CBRX, RMTR, STSA, DVAX Lower
-
Oct 23, 2009 10:36 AM
Elan (ELN) and Biogen (BIIB) Weak On Jump In Tysabri PML Cases
-
Oct 20, 2009 07:22 AM
Biogen (BIIB) Tops Q3 Views; Announces $1B Buyback; Guides FY09
View All Reports
StreetInsider Reports on BIIB by Category
-
Nov 16, 2009 08:39 AM
H&Q Healthcare Investors Closed-End Fund Decently Valued
-
Nov 9, 2009 05:07 AM
U.S. Healthcare Legislation Investment Impact
-
Nov 3, 2009 10:35 AM
Spectrum Pharma: CMS Rules in Favor of Zevalin
-
Nov 2, 2009 12:50 PM
Analyst upgrades, downgrades and initiations: CMCSA, CS, JWN, RCL, RIMM, YUM ...
-
Oct 30, 2009 08:39 AM
Healthcare Profits: Assessing Company Sensitivity to Obamacare
View All Blogs
Comments on BIIB
No comments are currently available.
on Sep 21, 2009
at 07:20 PM Dell and Perot Interesting
Article: Notable Mergers and Acquisitions of the Day 9/21: DELL/PER, HK, IMA, BIIB/FACT
on Jan 29, 2009
at 07:08 PM Clueless! They probably have large investments in TEVA Pharmaceuticals
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell
on Jan 29, 2009
at 06:16 AM What a bunch of Idiots Who would listen to a sub par investment bank like Brean Murray Carret? Disregard the sell - look at the pipeline! I'm expecting good earnings for Q4
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell
on Jan 28, 2009
at 09:10 PM re: 5 consecutive knockouts What are these guys thinking? BIIB will continue to surprise us with top notch earnings and a terrific pipeline.
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell
on Oct 28, 2008
at 09:45 AM bout time Finally someone realises the value. This stock is cheaper than in 95 although earnings have grown, company has bought in stock, and it is a good takeover prospect. Even in a deep recession they will do well. Suffering from the Dow blues, margin calls, and hedge fund unwinding, this stock will bounce high.
Article: Cowen & Co Upgrades Biogen Idec (BIIB) to Outperform, Calls Best Value In Biotech